Fig. 3.

Survival curves for antibody-treated mice. Panel a, survival of AG129 mice that were passively transferred intraperitoneally 127 μg of m2C9 (■), 2C9-cIgG (●), 2C9-cIgM (◆), or PBS (▲), 24 hours prior to i.p. challenge with 17D-204. Clinical signs began after 11 days p.i. so graphs show surviving animals from days 12 to 31, after which experiments were terminated. Panel b, survival of AG129 mice challenged i.p. with 17D-204 and administered i.p. 127 μg of m2C9 (■) or 2C9-cIgG (●) at 24 h or m2C9 (□) or 2C9-cIgG (○) 72 h p.i. A survival curve for PBS control mice is included for comparison (▲). Mice were monitored as in Panel a.